Matrix Trust Co grew its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 306.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 459 shares of the medical research company’s stock after purchasing an additional 346 shares during the period. Matrix Trust Co’s holdings in Amgen were worth $120,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently made changes to their positions in AMGN. Pathway Financial Advisers LLC increased its holdings in Amgen by 33,125.4% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company’s stock valued at $1,437,115,000 after buying an additional 4,446,757 shares during the period. International Assets Investment Management LLC increased its stake in Amgen by 6,812.4% in the third quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company’s stock valued at $8,130,610,000 after acquiring an additional 2,486,882 shares during the period. Assenagon Asset Management S.A. increased its stake in Amgen by 561.5% in the third quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company’s stock valued at $496,117,000 after acquiring an additional 1,306,982 shares during the period. Granite Bay Wealth Management LLC lifted its stake in Amgen by 9,058.1% during the second quarter. Granite Bay Wealth Management LLC now owns 756,460 shares of the medical research company’s stock worth $223,897,000 after purchasing an additional 748,200 shares during the period. Finally, Nordea Investment Management AB boosted its holdings in Amgen by 40.7% during the fourth quarter. Nordea Investment Management AB now owns 2,338,665 shares of the medical research company’s stock valued at $609,526,000 after purchasing an additional 676,598 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.
Wall Street Analyst Weigh In
Several research firms recently commented on AMGN. Leerink Partners cut their target price on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Citigroup cut their price objective on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Finally, Wells Fargo & Company decreased their price objective on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research note on Friday. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average target price of $314.91.
Amgen Stock Performance
AMGN stock opened at $270.19 on Tuesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company has a market cap of $145.24 billion, a P/E ratio of 34.60, a price-to-earnings-growth ratio of 2.91 and a beta of 0.56. The business’s fifty day moving average is $278.16 and its 200-day moving average is $308.35.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion for the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue was up 23.2% compared to the same quarter last year. During the same quarter last year, the business earned $4.96 earnings per share. Equities research analysts forecast that Amgen Inc. will post 19.53 EPS for the current year.
Amgen Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 annualized dividend and a yield of 3.52%. The ex-dividend date of this dividend is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is presently 121.90%.
Amgen Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Featured Stories
- Five stocks we like better than Amgen
- Retail Stocks Investing, Explained
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- How to Most Effectively Use the MarketBeat Earnings Screener
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- There Are Different Types of Stock To Invest In
- Delta Can Fly to New Highs in 2025; Here’s Why
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.